Skip to main content
. 2017 Feb 21;292(15):6202–6212. doi: 10.1074/jbc.M116.772996

Table 2.

Potency of grazoprevir against a panel of replicons bearing NS3/4A from HCV genotypes 1–6 reference sequences

Replicon EC50 ± S.D.a
nm
GT1a (H77; NC_004102) 0.4 ± 0.3
GT1b (Con1; AJ238799) 0.5 ± 0.3
GT2a (JFH-1; AB047639) 2.3 ± 1.2
GT2b (MD6; AY232740) 3.7 ± 1.1
GT2b (MD2; AY232732) 2.9 ± 0.4
GT3a (S52; GU814263)b 2.1 ± 1.0
GT3a (S52; GU814263) 35.0 ± 15
GT4a (ED43; GU814265) 0.3 ± 0.2
GT5a (SA1; KJ925150 0.4 ± 0.1
GT6 (GZ52557; DQ278892) 0.2 ± 0.04

a The standard deviation is n ≥ 3.

b The chimeric replicon bearing the catalytic domain of GT3a NS3 is in the GT2a_JFH-1 background.